A Phase II Study of Abemaciclib in Patients with Recurrent Brain Tumors

Full Title

A Phase 2 Study of Abemaciclib in Patients with Recurrent Primary Brain Tumors

Purpose

The purpose of this study is to assess the safety and effectiveness of the investigational drug abemaciclib in patients with brain tumors that have come back despite prior radiation therapy and/or chemotherapy. The study will include patients with glioma, meningioma, ependymoma, primary central nervous system lymphoma, and other brain tumor types.

Abemaciclib is an investigational drug designed to inhibit cancer growth by blocking cyclin-dependent kinases (CDK), enzymes which cancer cells need to grow and divide. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a brain tumor that has come back or continued to grow despite prior treatment.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Thomas Kaley at 212-639-5122 or the Brain Tumor Hotline at 212-639-6767.

Protocol

17-261

Phase

II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators